Back to discover
Drug

Glycerol

In clinical development
Emerging researchLate-stage development
Also known as Abreva Rapid Pain Relief, Aci-Jel, Blink Dry Eye, Cepacol Sore Throat Spray+26 more

Abreva Rapid Pain Relief, Aci-Jel, Blink Dry Eye, Cepacol Sore Throat Spray, Chloraseptic Max Spray, Colace Glycerin Suppositories, Glycerin Suppositories, Glycerin Topical, Glycerine, Glycerinum, Glyzerin, Monoctanoin component D, Oasis Tears, Osmoglyn, Pedia-Lax Liquid Glycerin Suppositories, Pretz, ProcalAmine 3, Propanetriol, Recticare Wipes, Regener-Eyes, Sani-Supp, Soothe Lubricant Eye Drops, Tears Naturale Forte, Trihydroxypropane, glycérine, Ölsüß, GLYCERIN, glycérol, 1,2,3-propanetriol, 1,2,3-trihydroxypropane.

1
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Atmospheric kraft pulping in glycerol

Industry2026-07-11Nature — Environmental Sciences

Lactate and Glycerol Contribution to Gluconeogenesis

Clinical trial2025-12-02Results expected Q2 2029 · ClinicalTrials.gov

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Clinical trial2020-01-23Results posted · ClinicalTrials.gov

Training Effects on Skeletal Muscle Fatty Acid Metabolism

Clinical trial2015-07-23Results posted · ClinicalTrials.gov

Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.

Research2009-04-23Journal of the American Society of Nephrology : JASN

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Glycerol
Aliases & brands
Abreva Rapid Pain ReliefAci-JelBlink Dry EyeCepacol Sore Throat SprayChloraseptic Max SprayColace Glycerin SuppositoriesGlycerin SuppositoriesGlycerin TopicalGlycerineGlycerinumGlyzerinMonoctanoin component DOasis TearsOsmoglynPedia-Lax Liquid Glycerin SuppositoriesPretzProcalAmine 3PropanetriolRecticare WipesRegener-EyesSani-SuppSoothe Lubricant Eye DropsTears Naturale ForteTrihydroxypropaneglycérineÖlsüßGLYCERINglycérol1,2,3-propanetriol1,2,3-trihydroxypropane
RxNorm CUI
4910
ChEMBL ID
CHEMBL692
ATC codes
A06AX01A06AG04
UNII
PDC6A3C0OX

Clinical trials

17 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
17
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
2
Recruiting
14
Late-stage (III+)
9
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 17
Phase 11Phase 1 / 21Phase 21Phase 32Phase 45Phase N / A7

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.

Journal of the American Society of Nephrology : JASN · 2009 · 997 cites
Recent papers

Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.

Journal of the American Society of Nephrology : JASN · 2009 · 997 cites
Journals, researchers & institutions
Top journals
  • Journal of the American Society of Nephrology : JASN1
Leading researchers
  • Bruno S1
  • Busca A1
  • Bussolati B1
  • Calogero RA1
  • Camussi G1
  • Collino F1
  • Deregibus MC1
  • Falda M1
Leading institutions
free-text, unnormalised
  • Research Center for Experimental Medicine1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials